Ignite Creation Date:
2024-05-05 @ 9:43 PM
Last Modification Date:
2024-10-26 @ 10:08 AM
Study NCT ID:
NCT00942058
Status:
TERMINATED
Last Update Posted:
2014-01-29
First Post:
2009-06-17
Brief Title:
Serum CA9 Level as Biological Marker of the Treatment Response in Metastatic Renal Cell Cancer
Sponsor:
Centre Hospitalier Universitaire de Saint Etienne
Organization:
Centre Hospitalier Universitaire de Saint Etienne
Study Overview
Official Title:
Serum Carbonic Anhydrase 9 CA9 Level as Biological Marker of the Treatment Response in Metastatic Renal Cell Cancer a Pilot Study
Status:
TERMINATED
Status Verified Date:
2014-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Difficult for recruiting
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CA9CRM
Brief Summary:
One third of patients with kidney cancer are diagnosed in the metastatic stage and among patients with a localized form about 30 to 40 will develop metastases after surgery
Medical treatment of metastatic renal cancer include immunotherapy with interferon α andor IL-2 or targeted therapies such as anti-angiogenic anti-vascular endothelial growth factor VEGF anti-tyrosine kinase inhibitors and m-TOR These treatments sometimes associated or IL2 INF or INF AntiVEGF do allow for objective response in 15 to 30 of cases net benefit of targeted therapies but are carriers of potentially significant side effects and are very expensive The treatment response is considered on imaging exams repetitive costly and inconsistently reliable A serum marker of tumor development would be particularly welcome
CA9 is an oncogene also know as CA IX carbonic anhydrase 9 or MNCA9 The gene encoding an oncoprotein called indifferently membrane antigen MN MNCA9 isoenzyme carbonic anhydrase IX CA9 G250MNCA9 or protein G250 It was demonstrated that the level of expression of CA9 in tumor tissue can be used as a predictive marker of response to immunotherapy
In previous studies the investigators tried to use CA9 to improve the differential diagnosis of kidney tumors using tumor biopsy or fine needle aspiration More recently the investigators have developed the ELISA and quantitative reat time polymerase chain reaction RT-PCR to study the CA9 protein and CA9 mRNA in the serum of patients with non-metastatic kidney cancer The investigators have thus shown that CA9 was overexpressed prior to surgery and that this expression disappeared after tumor ablation
Medical treatment of metastatic renal cancer include immunotherapy with interferon α andor IL-2 or targeted therapies such as anti-angiogenic anti-vascular endothelial growth factor VEGF anti-tyrosine kinase inhibitors and m-TOR These treatments sometimes associated or IL2 INF or INF AntiVEGF do allow for objective response in 15 to 30 of cases net benefit of targeted therapies but are carriers of potentially significant side effects and are very expensive The treatment response is considered on imaging exams repetitive costly and inconsistently reliable A serum marker of tumor development would be particularly welcome
CA9 is an oncogene also know as CA IX carbonic anhydrase 9 or MNCA9 The gene encoding an oncoprotein called indifferently membrane antigen MN MNCA9 isoenzyme carbonic anhydrase IX CA9 G250MNCA9 or protein G250 It was demonstrated that the level of expression of CA9 in tumor tissue can be used as a predictive marker of response to immunotherapy
In previous studies the investigators tried to use CA9 to improve the differential diagnosis of kidney tumors using tumor biopsy or fine needle aspiration More recently the investigators have developed the ELISA and quantitative reat time polymerase chain reaction RT-PCR to study the CA9 protein and CA9 mRNA in the serum of patients with non-metastatic kidney cancer The investigators have thus shown that CA9 was overexpressed prior to surgery and that this expression disappeared after tumor ablation
Detailed Description:
We propose a pilot study of CA9 serum in patients with adenocarcinoma metastatic cell treated by conventional immunotherapy and or targeted therapy This pilot study aims to test the CA9 serum marker of response to medical treatment
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2008-A01125-50 | OTHER | AFSSAPS | None |